Gemigliptin/metformin - LG Chem

Drug Profile

Gemigliptin/metformin - LG Chem

Alternative Names: FDC (gemigliptin/metformin HCl sustained release) - LG Chem; Metformin/gemigliptin; ZemiMet SR

Latest Information Update: 08 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator LG Life Sciences
  • Developer LG Chem
  • Class Antihyperglycaemics; Biguanides; Piperidines; Pyrimidines; Small molecules
  • Mechanism of Action AMP activated protein kinase stimulants; CD26 antigen inhibitors; Gluconeogenesis inhibitors; Glucose modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Type 2 diabetes mellitus

Most Recent Events

  • 12 Jan 2018 LG Chem completes a phase I PK/PD trial for Healthy Volunteers in South Korea (PO) (NCT03355014)
  • 13 Dec 2017 LG Chem initiates a phase I PK/PD trial for Healthy Volunteers in South Korea (PO) (NCT03355014)
  • 28 Nov 2017 LG Chem plans a phase I PK/PD trial for Healthy Volunteers in December 2017 (PO) (NCT03355014)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top